Letter Agreement, dated as of October 30, 2023, by and between Lung Therapeutics, Inc. and Charles T. Garner
Exhibit 10.2
LUNG THERAPEUTICS, INC.
October 30, 2023
Charles Garner
[***]
[***]
Dear Mr. Garner:
As you know, Lung Therapeutics, Inc. (the “Company”) previously entered into an Employment Agreement with you dated December 13, 2018 (the “Agreement”). The Company desires to modify the Agreement effective October 30, 2023, as follows:
In addition, you agree that any change in your title, duties, responsibilities or position that are effectuated at the closing of the merger under which the Company (or a successor thereof) becomes a wholly-owned subsidiary of Aileron Therapeutics, Inc. (“ALRN”), in and of itself, does not fall within the definition of “Good Reason” as set forth in Section 1.6.5 of the Agreement. You further acknowledge and agree that, following the merger, you will cease to hold the office of Chief Financial Officer of the Company, and will report to Brian Windsor, President and Chief Operating Officer of ALRN. You are not waiving any other rights you may have as it relates to Sections 1.6, 1.7, and 1.8 of the Agreement.
If you wish to accept this amendment, please sign and date a copy of this letter and return it to the Company.
1
Very truly yours,
LUNG THERAPEUTICS, INC.
By: /s/ Aaron Fletcher
Name: Aaron Fletcher
Title: Director
ACCEPTED AND AGREED:
Charles Garner
/s/ Charles Garner
Signature
October 30, 2023
Date
2
